durect.com - צמיחת מכירות משנה לשנה (TTM) DRRX

סמל מסחרי של DURECT Corp (DRRX)

DURECT Corporation expenses are based on strict compliance with environmental standards for bio-waste disposal. The rolling 12-month sales growth rate year-over-year visualizes revenue dynamics, where the value -60.60 describes the current level. The company's potential relies on epigenetic treatment for alcoholic hepatitis, although geopolitical isolation and sanctions significantly hinder global clinical trials and drug logistics.

DRRX - צמיחת מכירות משנה לשנה (TTM) DURECT בטווח 11.02.2024 - 20.02.2024

DURECT - פילוחים אנליטיים ומדדי מפתח (DRRX)

- שער מניה ותחזית מחירי מומחים:
הערכת שווי פונדמנטלית של החברה:durect.com
מוצר סדרתי של durect.com

Strategic alliances of DURECT Corporation in the development of larsucofibrate determine the pace of commercialization for its drugs. The annual revenue growth trend over the TTM period reflects the effectiveness of these partnerships through the lens of current cash flows. This metric compares total revenue over the last 12 months with the same prior period, neutralizing quarterly seasonality. Investors can see the actual speed of business scaling in real-time. This allows for the timely recognition of a sales cycle reversal.